Novel Approaches for the Treatment of Nephrogenic Diabetes Insipidus (NDI)
This invention discloses a novel set of interactions between the prostaglandin and purine signaling pathways that reveal a new class of drug targets for future NDI therapies.Benefits
Nephrogenic Diabetes Insipidus (NDI) can be acquired as a result of the use of medicines such as lithium for bipolar disorders, or others such as cisplatin, puromycin, adriamycin, calcium channel blockers, and amphotericin B. Conditions such as chronic kidney disease, electrolyte disorders (high calcium or low potassium levels in the blood), ureteral obstruction (prostatic hypertrophy), and a low protein diet can also cause NDI.
Many of the prescribed therapies for NDI have undesirable or even counterproductive side effects. For example, thiazide diuretics or prostaglandin inhibitors may cause lithium retention in patients on such therapy and even cause renal damage, thereby exacerbating the symptoms of NDI. In response, this invention defines improved therapeutic agents for the treatment of acquired NDI. By reducing prostaglandin synthesis in the kidney�s collecting ducts, this invention provides a superior alternative for these therapies.
Stage of Development
*A provisional patent application has been filed with the U.S. Patent and Trademark Office. The technology is available for licensing and/or developmental support under exclusive or non-exclusive terms.
Additional Info
� Welch et al. �P2Y2 receptor-stimulated release of prostaglandin E2 by rat inner medullary collecting duct preparations�, Am. J. Physiol. Renal Physiol. 285: F711-F721, 2003.
*Schwiebert and Kishore. Extracellular nucleotide signaling along the renal epithelium (Invited Review), Am. J. Physiol. Renal Physiol. 280: F945-F963, 2001.
*Kishore, et al. �Molecular physiology of urinary concentration defect in elderly population�Intl. Urology & Nephrology 33: 235-248, 2001.
Inventor(s): Raoul Nelson, Noel Carlson, Donald Kohan, Bellamkonda Kishore
Type of Offer: Licensing
« More Medical Patents